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Abstract
Rationale Drugs of abuse are initially used because of their
rewarding properties. As a result of repeated drug exposure,
sensitization to certain behavioral effects of drugs occurs,
which may facilitate the development of addiction. Recent
studies have implicated the metabotropic glutamate receptor
5 (mGlu5 receptor) in drug reward, but its role in
sensitization is unclear. Stimulation of dopamine receptors
plays an important role in drug reward, but not in the
sensitizing properties of cocaine and morphine.
Objective This study aims to evaluate the role of mGlu5
and dopamine receptors in the development of cocaine- and
morphine-induced conditioned place preference (CPP) and
psychomotor sensitization.
Materials and methods Rats were treated with the mGlu5
receptor antagonist MTEP (0, 1, 3, and 10 mg/kg, i.p.) or the
dopamine receptor antagonist α-flupenthixol (0, 0.125, 0.25,
and 0.5 mg/kg, i.p.) during place conditioning with either
morphine (3 mg/kg, s.c.) or cocaine (15 mg/kg, i.p.).
Furthermore, MTEP (1 mg/kg, i.p.) or α-flupenthixol
(0.5 mg/kg, i.p.) was co-administered during cocaine (30 mg/
kg, i.p.) or morphine (3.0 mg/kg, s.c.) pretreatment and
psychomotor sensitization was tested 3 weeks post-treatment.
Results MTEP attenuated the development of morphine-
but not cocaine-induced CPP. In contrast, MTEP sup-
pressed the development of cocaine- but not morphine-
induced psychomotor sensitization. α-Flupenthixol blocked
the development of both cocaine- and morphine-induced
CPP but did not affect the development of sensitization to
either drug.
Conclusion Dopamine receptor stimulation mediates co-
caine and morphine reward but not sensitization. In
contrast, the role of mGlu5 receptors in reward and
sensitization is drug-specific.
Keywords Morphine . Cocaine . Dopamine receptor .
Metabotropic glutamate receptor . Locomotor activity .
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Introduction
Over the last two decades, a substantial body of evidence
implicating glutamatergic neurotransmission in the devel-
opment and expression of neuroplastic changes underlying
drug addiction has accumulated (Wolf 1998; Vanderschuren
and Kalivas 2000; Kalivas 2009; Schmidt and Pierce 2010).
Glutamate can bind to two distinct receptor types: the
ionotropic glutamate receptors (iGlu receptors) and the
metabotropic glutamate receptors (mGlu receptors)
(Spooren et al. 2003; Kew and Kemp 2005). Most research
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on the role of glutamate in addictive behavior has focused
on iGlu receptors, and although studies have shown that
iGlu receptors are involved in drug reward and sensitization
(Vanderschuren and Kalivas 2000; Wolf 1998; Gass and
Olive 2008; Schmidt and Pierce 2010) clinical trials have
thus far been unsuccessful in identifying iGlu receptor
ligands that effectively treat addiction (Bisaga et al. 2000;
Tzschentke 2002; Heidbreder and Hagan 2005).
Recent studies have identified mGlu receptors as potential
targets for the treatment of drug addiction. Eight different
subtypes of this receptor have been described, of which the
metabotropic glutamate 5 receptor (mGlu5 receptor) has been
most prominently implicated in addictive behavior (Kenny
and Markou 2004; Spooren et al. 2003; Gass and Olive
2008). For instance, the mGlu5 receptor antagonist 2-
methyl-6-(phenylethynyl)-pyridine (MPEP) has been shown
to block the development of cocaine- and morphine-
conditioned place preference (CPP) (Popik and Wrobel
2002; Herzig and Schmidt 2004; Aoki et al. 2004), although
in one study the effect of MPEP on drug-induced CPP was
specific for cocaine; i.e., morphine, nicotine, amphetamine,
and alcohol CPP were not affected (McGeehan and Olive
2003). Furthermore, mGlu5 receptor knockout mice do not
self-administer cocaine (Chiamulera et al. 2001) and MPEP
or the structurally related mGlu5 receptor antagonist 3-[(2-
methyl-1, 3-thiazol-4-yl) ethynyl] pyridine (MTEP) de-
creased self-administration of different drugs of abuse,
including cocaine, metamphetamine, heroin, alcohol, nico-
tine, and ketamine under fixed-ratio schedules of reinforce-
ment (Paterson et al. 2003; Tessari et al. 2004; Olive et al.
2005; Kenny et al. 2005; Schroeder et al. 2005; van der Kam
et al. 2007; Gass et al. 2009; Martin-Fardon et al. 2009). In
addition, MPEP and MTEP were also found to reduce
breakpoints in animals responding for cocaine, methamphet-
amine, alcohol, and nicotine under a progressive ratio
schedule of reinforcement, whereas the effects on responding
for food were inconsistent between studies (Paterson and
Markou 2005; Besheer et al. 2008; Gass et al. 2009).
Together, these studies suggest that the mGlu5 receptor is
critically involved in -drug reinforcement.
The mGlu5 receptor has also been implicated in drug-
induced psychomotor hyperactivity. The psychomotor stimu-
lant effect of cocaine is absent in mGlu5 receptor knockout
mice (Chiamulera et al. 2001) and MPEP decreases the acute
psychomotor effects of cocaine, amphetamine, and nicotine
(McGeehan et al. 2004; Herzig and Schmidt 2004; Tessari
et al. 2004). The psychomotor stimulant effects of drugs of
abuse are well known to persistently increase after repeated
drug administration, a phenomenon known as behavioral
sensitization (Stewart and Badiani 1993; Robinson and
Berridge 1993; Vanderschuren and Kalivas 2000). Since it
is thought that behavioral sensitization is an important
driving factor in the development of drug addiction
(Robinson and Berridge 1993, 2003; Vanderschuren and
Pierce 2010), it is of interest to investigate the involvement
of the mGlu5 receptor in psychomotor sensitization. Previ-
ous studies have shown that MPEP and MTEP attenuate the
expression of morphine-, cocaine-, and nicotine-induced
psychomotor sensitization (Tessari et al. 2004; Kotlinska
and Bochenski 2007; Kotlinska and Bochenski 2009).
However, the role of the mGlu5 receptor in the development
of sensitization has remained unexplored. In this regard, it is
of interest that mGlu5 receptors have been shown to be
involved in the neuroplastic changes underlying learning
(Fendt and Schmid 2002; Rodrigues et al. 2002; Gravius
et al. 2005; Xu et al. 2009). In view of the mechanistic
similarities between drug- and experience-induced behavior-
al plasticity (Kelley 2004; Hyman et al. 2006), it is possible
that mGlu5 receptors are also involved in the development of
psychomotor sensitization.
The aim of the present study was to further evaluate the
role of the mGlu5 receptor in drug reward and the
development of sensitization. To this end, we investigated
the effect of the mGlu5 receptor antagonist MTEP and the
dopamine receptor antagonist α-flupenthixol on the induction
of morphine- and cocaine-induced CPP and psychomotor
sensitization. Since the role of dopamine in reward and
sensitization is well established, we included the dopamine
receptor antagonist in this study for comparison. Mesolimbic
dopamine has been widely implicated in the rewarding effects
of drugs of abuse (Koob et al. 1998; Wise 2004; Pierce and
Kumaresan 2006), but it does not play a critical role in the
development of sensitization of the psychomotor stimulant
properties of cocaine and morphine (Vanderschuren and
Kalivas 2000). Furthermore, it has been shown that mGlu5
receptor stimulation can raise extracellular dopamine in
prefrontal cortex and striatum, which can be blocked by,
for instance, MPEP or the general mGluR antagonist (+)-
MCPG (Bruton et al. 1999; Renoldi et al. 2007). Thus,
mGlu5 receptor blockade may reduce the ability of cocaine
or morphine to enhance mesolimbic dopamine neurotrans-
mission which may, in turn, attenuate the rewarding effects
of these drugs—although cocaine did increase nucleus
accumbens dopamine overflow in mGlu5 receptor
knockout mice (Chiamulera et al. 2001). We chose to test
two types of drug of abuse that differ in their initial actions
on the central nervous system. Cocaine inhibits the reuptake
of dopamine, serotonin, and noradrenalin into the
presynaptic terminal, causing an accumulation of these
neurotransmitters in the synaptic cleft and a prolonged
receptor stimulation (Heikkila et al. 1975; Ritz et al. 1987),
and morphine is an agonist at mu-opioid receptors.
Based on the studies described above, we hypothe-
sized that the mGlu5 receptor is involved in both drug
reward and sensitization, while dopamine receptors play
a role in reward but not in sensitization. Therefore, we
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expected that both α-flupenthixol and MTEP would
block the development of cocaine- and morphine-
induced CPP and that MTEP but not α-flupenthixol




Male Wistar rats (Charles River, Sulzfeld, Germany)
weighing 170±15 g upon arrival in the laboratory were
used for all experiments. The animals were housed two per
cage (Macrolon cages, 40×26×20 cm) in climate-
controlled rooms (temperature, 21±2°C; 60–65% relative
humidity) under a 12-h day/night cycle with lights on at
7 am. Regular chow (SDS, England) and water were
available ad libitum. The animals were allowed to habituate
to the housing conditions for at least 1 week and were
handled three times prior to the experiment. Two days
before testing, the rats were moved to the experimental
room. The experiments were approved by the Animal
Ethics Committee of Utrecht University, the Netherlands,
and were conducted in agreement with Dutch laws (Wet op




The place conditioning apparatus (TSE Systems, Bad
Homburg, Germany) consisted of three compartments, and
each compartment differed with regard to visual and tactile
cues. Two equally sized compartments were used for place
conditioning (30×25×30 cm, l×w×h). The first condition-
ing compartment had black walls, a fine metal mesh floor,
and white light (2 W) in the Plexiglas lid to achieve a
comparable light intensity in both conditioning compart-
ments, while the other conditioning compartment had walls
with black and white stripes, a wide metal mesh floor, and
no light in the Plexiglas lid. Pilot studies performed in our
laboratory have shown that the rats had no consistent
unconditioned preference for one of the compartments, i.e.,
there was not one particular compartment that was preferred
by the majority of animals during the pretest (see below).
The third, middle compartment (10×25×30 cm) was only
used for introducing the animal into the apparatus during
the pretest and test sessions. This middle compartment had
white walls, a smooth floor, and white light (2 W) in the
Plexiglas lid. During the pretest and test sessions, arched
gateways gave access to the two adjacent conditioning
compartments, which allowed the animals to freely move
around the entire apparatus. During conditioning sessions,
the rats were placed in one of the two conditioning
compartments and access to the other compartments was
blocked by inserting dividers without a gateway between
the compartments. All compartments were equipped with
photo-sensors which detect the location of the animals, and
TSE software was used to calculate the total time spent in
each compartment.
Procedure
The experiments consisted of three phases: a pretest (session
1), a conditioning period (session 2–9), and a test phase
(session 10). The sessions took place once per day and 5 days
per week. During the pretest, that took place under drug-free
conditions, the rats were free to explore the entire apparatus
for 15 min. At the beginning of the pretest the animals were
placed in the middle, neutral compartment and we measured
the time they spent in each compartment. The rats that spent
more than 500 s in one conditioning compartment were
excluded from the experiment (in total, 4% of all rats tested).
The remaining animals were divided into four groups
according to a counterbalanced design (Tzschentke 2007).
Thus, on the basis of their pretest scores (i.e., time spent in
the two conditioning compartments during the pretest), the
rats were assigned to a compartment in which they would
receive drug treatment, so that the baseline preference in
each test group for the (to be) drug-paired and (to be) saline-
paired compartments approximated 50%. Thus, some rats,
based on the pretest scores, would be conditioned in their
preferred compartment, but others would be conditioned in
their non-preferred compartment. This procedure rules out
the possibility that preference shifts are the result of
decreased avoidance of the non-preferred compartment.
During place conditioning, the rats received four drug-
paired sessions (session 2, 4, 6, and 8) and four saline-paired
sessions (session 3, 5, 7, and 9). The first experiment was
performed in order to determine if the doses of α-
flupenthixol or MTEP used would induce CPP or condi-
tioned place aversion (CPA) by themselves. Before the start
of drug-paired sessions, the rats were injected with one of
the following drugs: α-flupenthixol (0 or 0.5 mg/kg, i.p.),
30 min later followed by a saline (1.0 ml/kg, i.p.) injection;
MTEP (0 or 10 mg/kg, i.p.), 20 min later followed by a
saline injection (1.0 ml/kg, i.p.). Immediately after the saline
injection, the animals were placed into the drug-paired
compartment for 40 min. Before the start of saline-paired
sessions, the rats were injected twice with saline (1.0 ml/kg,
i.p.), 20 (in the MTEP experiment) or 30 min (in the α-
flupenthixol experiment) apart. The time points of the
injections during the saline sessions matched the time point
of the injections during the drug-paired sessions. Session 10
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consisted of a 15-min test where animals could freely move
around the entire apparatus. This test session was carried out
under drug-free conditions. Similar as in the pretest-session,
the animals were introduced into the apparatus by placing
them in the middle, neutral compartment. Next, we measured
the time spent in each compartment. In the second set of
experiments, we determined the effect of MTEP and α-
flupenthixol on cocaine- and morphine-induced place con-
ditioning. Before the start of drug pairing sessions, the rats
were injected with one of the following drug combinations:
α-flupenthixol (0, 0.125, 0.25, or 0.5 mg/kg, i.p.) 30 min
before a cocaine (15 mg/kg, i.p.) or morphine injection
(3 mg/kg, s.c.) or MTEP (0, 1, 3, or 10 mg/kg, i.p.) 20 min
before a cocaine (15 mg/kg, i.p.) or morphine injection
(3 mg/kg, s.c.). Directly after the second injection (i.e.,
cocaine or morphine), the animals were placed in the drug-
paired compartment for 40 min. Vehicle-paired sessions and
the test sessions were carried out as described above. The
doses of cocaine and morphine were based on pilot studies.
Thus, 15 mg/kg cocaine was the lowest dose that induced
robust and reproducible CPP, whereas CPP could be induced
with morphine at doses of 1 mg/kg and higher.
Psychomotor sensitization
Apparatus
The locomotor activity of rats was measured in open-field
test cages (50×35×40 cm). The horizontal distance traveled
was tracked automatically using a video tracking system
(Ethovision, Noldus Information Technology BV, Wage-
ningen, Netherlands) which determined the position of the
animals five times per second.
Procedure
To determine the effect of MTEP and α-flupenthixol on the
induction of cocaine psychomotor sensitization, the rats
were pretreated in open-field cages for five consecutive
days. During pretreatment sessions, the animals were first
allowed to habituate to the open field for 30 min, after
which they received an injection of α-flupenthixol (0.5 mg/
kg, i.p.), MTEP (1 mg/kg, i.p.), or saline (1 ml/kg, i.p.). At
30 min after the administration of α-flupenthixol or 20 min
after the administration of MTEP, the rats were injected
with either cocaine (30 mg/kg, i.p.) or saline. The
pretreatment dose of cocaine used was based on pilot
studies. Thus, we observed robust and reproducible
sensitization after repeated treatment with 30 mg/kg (but
not 15 mg/kg) cocaine. At 3 weeks after the last
pretreatment session, the rats were challenged with cocaine.
The challenge session started with a 30-min habituation
period. Next, the animals were injected with saline (1 ml/
kg, i.p.), and they were injected with cocaine (10 mg/kg,
i.p.) 30 min later. The locomotor activity of the animals
during all sessions was monitored from the time of
introduction to the open field until 60 min after the cocaine
injection. To determine the effect of MTEP and α-
flupenthixol on the induction of morphine psychomotor
sensitization, the animals were pretreated for ten sessions
(five sessions a week). During pretreatment sessions, the
animals were allowed to habituate to the open field for
30 min, after which they were injected with α-flupenthixol
(0.5 mg/kg, i.p.), MTEP (1.0 mg/kg, i.p.), or saline (1.0 ml/
kg, i.p.). At 30 min after the first injection, the rats were
injected with either morphine (3.0 mg/kg, s.c.) or saline
(1.0 ml/kg, s.c.). The pretreatment dose of morphine used
was based on pilot studies. Thus, we observed robust and
reproducible sensitization after repeated treatment doses of
1 mg/kg morphine and higher. At 3 weeks after the last
pretreatment session, the animals were challenged with
morphine (1.0 mg/kg, s.c.). The procedure of the challenge
session was similar to the cocaine challenge session
described above. During all sessions, locomotor activity
was monitored from the time of introduction to the open
field until 90 min after the last injection.
Statistics
Place conditioning data are expressed as mean time spent in
drug- or vehicle-paired compartments ± S.E.M. (in sec-
onds). Outliers, identified using Dixon outlier test, were
excluded from the analyses (1.6% of all animals). To
determine the occurrence of CPP, we analyzed each group
using Student’s t-test for paired samples, comparing the
time spent in the drug-paired with the time spent in the
saline-paired compartment. For the psychomotor sensitiza-
tion experiments, horizontal activity is expressed as mean ±
S.E.M. distance traveled (in centimeters). The locomotor
responses during the pretreatment sessions are presented as
mean ± S.E.M. distance traveled during 60 min after
cocaine or saline injection or as the mean ± S.E.M. distance
traveled during 90 min after morphine or saline injection.
Data were analyzed using a three-way repeated-measures
ANOVA with sessions as within-subjects factor and the
receptor antagonists (MTEP or α-flupenthixol) and the drug
used to induce psychomotor sensitization (cocaine or
morphine) as two between-subjects factors. During the
challenge sessions, the distance traveled was analyzed in
10-min blocks. Data were analyzed using a three-way
repeated-measures ANOVA with time blocks as within-
subjects factor and receptor antagonists (MTEP or α-
flupenthixol) and the drug used to induce psychomotor
sensitization (cocaine or morphine) as two between-subjects
factors. Post-hoc comparisons were made where appropri-
ate using Student–Newman–Keuls tests. Behavioral data
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were analyzed using SPSS 15.0. The criterion for statisti-
cally significant differences was set at p<0.05
Drugs
MTEP (3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine) was
a generous gift from Dr. Will Spooren (F. Hoffman-la Roche
Ltd, Basel, Switzerland). The MTEP doses used were based
on literature (Anderson et al. 2002; Cosford et al. 2003) and
pilot studies. MTEP, cocaine–HCl (Bufa BV, Uitgeest, The
Netherlands), morphine–HCl (OPG Regilabs bv, Utrecht,
The Netherlands), and cis-(Z)-α-flupenthixol dihydrochlor-
ide (Sigma, Zwijndrecht, The Netherlands) were dissolved in
sterile physiological saline (0.9% NaCl).
Results
Place conditioning effect of MTEP and α-flupenthixol
Figure 1 shows that MTEP and α-flupenthixol, at the highest
doses used in this study, did not induce CPP or CPA
compared with saline. Moreover, the animals repeatedly
treated with saline in both compartments of the place
conditioning apparatus did not develop a preference for
one compartment or the other, demonstrating that repeated
exposure to the apparatus did not induce a preference for one
particular set of environmental cues [MTEP: t(sal)7=−1.351
NS, t(MTEP)7=0.642 NS; α-flupenthixol t(sal)7=−0.742
NS, t(α-flupenthixol)7=−0.258 NS].
Effect of MTEP and α-flupenthixol on cocaine-induced
place conditioning
In animals pretreated with saline, cocaine induced signifi-
cant preference for the drug-paired compartment in both
experiments. The acquisition of cocaine-induced CPP was
not affected by MTEP. In this experiment, one rat from the
saline, one rat from the 3 mg/kg, and one rat from the
10 mg/kg group were excluded from analysis as outliers.
Figure 2a shows that cocaine-induced CPP was present in
all groups independent of MTEP treatment [sal: t6=5.413
p<0.01; 1 mg/kg MTEP: t7=4.066 p<0.01; 3 mg/kg
MTEP: t6=7.554 p<0.001; 10 mg/kg MTEP: t6=5.455
p<0.01]. On the other hand, α-flupenthixol attenuated
the acquisition of cocaine-induced CPP. In this experi-
ment, one animal from the 0.125 mg/kg α-flupenthixol
group was excluded as an outlier. Figure 2b shows that
cocaine no longer induced CPP when 0.25 and 0.5 mg/kg
α-flupenthixol was co-administered during conditioning
[sal: t15=3.134 P<0.01; 0.125 mg/kg flupenthixol: t13=
4.569 p<0.001; 0.25 mg/kg flupenthixol: t14=0.546 NS;
0.5 mg/kg flupenthixol: t14=1.590 NS].
Effect of MTEP and α-flupenthixol on morphine-induced
place conditioning
In animals pretreated with saline, morphine induced a
significant preference for the drug-paired compartment in
both experiments. The acquisition of morphine-induced
place preference was suppressed by MTEP. Figure 3a
shows that, when 1 and 3 mg/kg MTEP was co-
administered with morphine during conditioning, no
morphine-induced CPP developed [sal: t14=4.240 p<
0.05; 1 mg/kg MTEP: t13=1.346 NS; 3 mg/kg MTEP:
t14=0.382 NS]. However, 10 mg/kg MTEP did not
attenuate place preference [t14=2.381 p<0.05]. α-
Flupenthixol attenuated the acquisition of morphine-
induced CPP. Figure 3b shows that the highest dose of
α-flupenthixol significantly reduced morphine-induced
CPP [sal: t15=2.669 P<0.05; 0.125 mg/kg flupenthixol:
t15=6.104 P<0.001; 0.25 mg/kg flupenthixol: t14=4.890
P<0.001; 0.5 mg/kg flupenthixol: t15=1.677 NS].
Fig. 1 The effect of MTEP- and α-flupenthixol on place conditioning.
a Rats were conditioned with saline in both compartments (n=8) or with
10 mg/kg MTEP, i.p., in one compartment and saline in the other (n=8).
b Rats were conditioned with saline in both compartments (n=8) or
with 0.5 mg/kg α-flupenthixol, i.p., in one compartment and saline in
the other (n=8). Data are presented as mean ± S.E.M. time spent in
drug-paired and saline compartment on test day
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The effects of MTEP and α-flupenthixol on psychomotor
activity during cocaine and morphine pretreatment
Figure 4 shows the psychomotor effects of cocaine, MTEP,
and α-flupenthixol during the first and last (i.e., fifth) day
of pretreatment. Figure 4a shows that cocaine treatment
enhanced psychomotor activity during the pretreatment
sessions [F(cocaine)1,28=28.504 p<0.001], but no sensiti-
zation to cocaine was observed during pretreatment [F
(session×coc)1, 28=0.784 NS]. MTEP did not alter the
cocaine-induced psychomotor response [F(MTEP×co-
caine)1,28=2.190 NS; F (session×MTEP×coc)1,28=0.041
NS], neither did MTEP influence the psychomotor activity
by itself [F(MTEP)1,28=1.486 NS; F(session×MTEP)1,28=
0.240 NS]. Figure 4b shows that cocaine treatment
increased psychomotor activity during pretreatment ses-
sions [F(cocaine)1,32=36.827 p<0.001], that this effect of
cocaine did not sensitize [F(session×cocaine)1,32=0.008
NS], and that α-flupenthixol did not affect the cocaine-
induced psychomotor activity during the pretreatment
sessions [F(α-flupenthixol×cocaine)1,32=2.841 NS; F(ses-
sion×α-flupenthixol×cocaine)1,32=2.841 NS]. In addition,
α-flupenthixol itself did not influence psychomotor activity
[F(α-flupenthixol)1,32=4.052 NS; F(session×α-flupen-
thixol)1,32=0.008 NS].
Figure 5 shows the psychomotor effects of morphine,
MTEP, and flupenthixol during the first and last (i.e., tenth)
day of pretreatment. Figure 5a shows that MTEP did not
affect morphine-induced psychomotor activity during pre-
treatment. Sensitization to morphine was observed during
pretreatment since the morphine-induced psychomotor
Fig. 3 The effect of MTEP and α-flupenthixol on the development of
morphine-induced CPP. a Rats were conditioned with morphine
(3 mg/kg, s.c.) together with saline (0; n=15), or 1 (n=14), 3 (n=
15), or 10 (n=15) mg/kg, i.p. MTEP. b Rats were conditioned with
morphine (3 mg/kg, s.c.) together with saline (0; n=16), or 0.125 (n=
16), 0.25 (n=15), or 0.5 (n=16) mg/kg, i.p., α-flupenthixol. Data are
presented as mean ± S.E.M. time spent in drug- and saline-paired
compartment on test day. *p<0.05 for difference in time spent in drug-
paired and saline-paired compartment (Student’s t-test)
Fig. 2 The effect of MTEP and α-flupenthixol on the development of
cocaine-induced CPP. a Rats were conditioned with cocaine (15 mg/
kg, i.p.) together with saline (0; n=7), 1 (n=8), 3 (n=7), or 10 (n=7)
mg/kg, i.p., MTEP. b Rats were conditioned with cocaine (15 mg/kg, i.
p.) together with saline (0; n=16), 0.125 (n=14), 0.25 (n=15), or 0.5 (n=
15) mg/kg, i.p., α-flupenthixol. Data are presented as mean ± S.E.M.
time spent in drug- and saline-paired compartment on test day. *p<0.05
for difference in time spent in drug- and saline-paired compartment
(Student’s t-test)
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activity increased over sessions [F(morphine)1,19=10.296
p<0.01; F(session×morphine)1,19=16.716 p=0.001].
MTEP did not alter the morphine-induced psychomotor
activity during these sessions [F(MTEP×morphine)1,19=
1.965 NS; F(session×MTEP×morphine)1,19=0.503 NS]
and MTEP did not affect the activity by itself [F
(MTEP)1,19=0.274 NS; F(session×MTEP)1,19=1.965 NS].
Figure 5b shows that α-flupenthixol did not affect the
morphine-induced psychomotor activity during the pretreat-
ment sessions. During these sessions, morphine did not
induce an increase in psychomotor activity [F(mor-
phine)1,17=2.561 NS; F(session×morphine)1,17=3.349
NS]. The absence of morphine sensitization during pre-
treatment was caused by one control rat showing a highly
increased activity only during the tenth pretreatment
session. Treatment with α-flupenthixol did not affect the
morphine-induced psychomotor activity [F(α-flupen-
thixol×morphine)1,17 =0.007 NS; F(session×α-flupen-
thixol×morphine)1,17=0.004 NS] and did not affect
activity by itself [F(α-flupenthixol)1,17=1.709 NS; F(ses-
sion×α-flupenthixol)1,17=0.519 NS].
The effect of MTEP and α-flupenthixol
on cocaine- and morphine-induced psychomotor
sensitization
Figure 6a shows that, during the habituation phase of the
challenge session, there was an effect of cocaine pretreat-
ment [F(cocaine)1,28=4.714 p=0.039], but no effect of
MTEP pretreatment[F(MTEP)1,28=1.378 NS; F(MTEP×
cocaine)1,28=2.234 NS]. After the saline injection, there
was no effect of cocaine or MTEP pretreatment [F
(cocaine)1,28=0.000 NS; F(MTEP)1,28=0.070 NS], but
there was an interaction between cocaine and MTEP [F
(MTEP×cocaine)1,28=4.646 p<0.05]. Cocaine pretreat-
ment resulted in a sensitized psychomotor response to a
low dose of cocaine [F(cocaine)1,28=9.282 p<0.01; F(time
blocks × cocaine)1 ,28 = 16.158 p < 0.001], and co-
administration of MTEP during pretreatment suppressed
this sensitized cocaine-induced psychomotor response [F
(MTEP)1,28=8.506 p<0.01; F(time blocks×MTEP)1,28=
1.781 p<0.01; F(MTEP×cocaine)1,28=8.651 p<0.01; F
(time blocks×MTEP×cocaine)1,28=7.249 p<0.01].
Fig. 5 The effects of MTEP and α-flupenthixol on the locomotor
response to morphine during pretreatment. a Locomotor responses to
morphine (morp; 3.0 mg/kg, s.c.) or saline (sal) in rats treated 30 min
before with MTEP (1.0 mg/kg, i.p.) or saline (sal) (n=8 per group). b
Locomotor responses to morphine (morp; 3.0 mg/kg, s.c.) or saline (sal)
in rats treated 30 min before with α-flupenthixol (flu; 0.5 mg/kg, i.p.) or
saline (sal) (n=9 per group). Locomotor responses were measured on
days 1 and 10 of pretreatment. Data are presented as total distance
traveled (cm) in 1 h after morphine or saline, expressed in mean ± S.E.
Fig. 4 The effects of MTEP and α-flupenthixol on the locomotor
response to cocaine during pretreatment. a Locomotor responses to
cocaine (coc; 30 mg/kg, i.p.) or saline (sal) in rats treated 20 min before
with MTEP (1.0 mg/kg, i.p.) or saline (sal) (n=8 per group). b
Locomotor responses to cocaine (coc; 30 mg/kg, i.p.) or saline (sal) in
rats treated 30 min before with α-flupenthixol (flu; 0.5 mg/kg, i.p.) or
saline (sal) (n=9 per group). Locomotor responses were measured on
days 1 and 5 of pretreatment. Data are presented as total distance
traveled (cm) in 1 h after cocaine or saline, expressed in mean ± S.E.M.
Psychopharmacology (2011) 214:863–876 869
Figure 6b shows that cocaine-induced psychomotor
sensitization was not altered by α-flupenthixol pretreat-
ment. Neither cocaine nor α-flupenthixol pretreatment
affected the locomotor responses during the habituation
phase and after the saline challenge [habituation: F
(cocaine)1,32=0.184 NS; saline: F(cocaine)1,32=0.049
NS; habituation: F(α-flupenthixol)1,32=0.443 NS; saline:
F(flupenthixol)1,32=0.054 NS; habituation: F(α-flupen-
thixol×cocaine)1,32=1.925 NS; saline: F(α-flupenthixol×
cocaine)1,32=1.273 NS]. After the challenge with cocaine,
the animals pretreated with cocaine showed an increased
locomotor response [F(cocaine)1,32=8.863 p<0.01; F
( t ime b locks × coca ine ) 1 , 3 2 = 11 .550 p < 0 .001] .
α-Flupenthixol pretreatment did not influence this sensi-
tized response [F(α-flupenthixol)1,32=0.266 NS; F(time
blocks×α-flupenthixol)1,32 =0.669 NS; F(α-flupen-
thixol×cocaine)1,32=1.195 NS; F(time blocks×α-flupen-
thixol×cocaine)1,32=0.921 NS].
Figure 7a shows that morphine-induced locomotor sensi-
tization during the challenge session was not altered by
MTEP pretreatment. During the habituation phases and the
30 min after the saline injections, neither morphine nor
MTEP pretreatment affected the locomotor responses
[habituation: F(morphine)1,19=1.155 NS; F(MTEP)1,19=
0.330 NS; F(MTEP×morphine)1,19=0.161 NS; saline:
F(morphine)1,19=2.747 NS; F(MTEP)1,19=0.057 NS;
F(MTEP×morphine)1,19=0.803 NS]. After the challenge
with morphine, a sensitized locomotor response was
observed in morphine-pretreated animals [F(morphine)1,19=
16.373 p=0.001; F(time blocks×morphine)1,19=2.591 NS].
MTEP pretreatment did not alter morphine sensitization
[F(MTEP)1,19=0.845 NS; F(time blocks×MTEP)1,19=0.408
NS; F(morphine×MTEP)1,19=0.633 NS; F(session×
MTEP×morphine)1,19=0.669 NS].
Figure 7b shows that morphine-induced locomotor
sensitization during the challenge session was not altered
by α-flupenthixol pretreatment. Neither morphine nor α-
flupenthixol pretreatment influenced the locomotor
responses of the animals during the habituation phase and
after the saline injection of the challenge session [habitu-
ation: F(morphine)1,17=0.013 NS; F(α-flupenthixol)1,17=
3.189 NS; F(α-flupenthixol×morphine)1,17=0.278 NS;
saline: F(morphine)1,17=0.302 NS; F(α-flupenthixol)1,17=
0.845 NS; F(α-flupenthixol×morphine)1,17=1.085 NS].
The morphine challenge induced an increased locomotor
response in animals that were pretreated with morphine [F
(morphine)1,17=22.686 p<0.001; F(time blocks×mor-
phine) 1,17=2.775 p<0.05], but α-flupenthixol had no
influence on this response [F(α-flupenthixol)1,17=2.257




In the present study, we investigated the role of mGlu5 and
dopamine receptors in the rewarding and sensitizing
properties of cocaine and morphine. To that aim, we
administered the mGlu5 receptor antagonist MTEP and
the dopamine receptor antagonist α-flupenthixol during the
development of cocaine and morphine CPP and psycho-
motor sensitization. In agreement with our hypotheses, co-
administration of α-flupenthixol during place conditioning
with morphine and cocaine attenuated CPP, but
α-flupenthixol did not affect the development of cocaine-
and morphine-induced psychomotor sensitization.
However, the results with MTEP only partially con-
firmed our hypotheses. Co-administration of MTEP during
Fig. 6 a Locomotor responses to cocaine (10 mg/kg, i.p.), in animals
pretreated for 5 days with: saline plus saline (sal-sal; n=8), saline plus
30 mg/kg cocaine, i.p. (sal-coc; n=8), 1.0 mg/kg MTEP, i.p., plus
saline (mtep-sal; n=8) or 1.0 mg/kg MTEP, i.p., plus 30 mg/kg
cocaine, i.p. (mtep-coc; n=8) 3 weeks post-treatment. b Locomotor
responses to cocaine (10 mg/kg, i.p.) in animals pretreated for 5 days
with: saline plus saline (sal-sal; n=9), saline plus 30 mg/kg cocaine,
i.p. (sal-coc; n=9), 0.5 mg/kg α-flupenthixol, i.p., plus saline (flu-sal;
n=9), or 0.5 mg/kg α-flupenthixol, i.p., plus 30 mg/kg cocaine, i.p.
(flu-coc; n=9), 3 weeks post-treatment. Data are presented as mean ±
S.E.M. distance traveled (in cm) per 10 min during habituation to the
test cages (10–30 min), after a saline injection (40–60 min), and after
the cocaine challenge (10 mg/kg, i.p., 70–120 min)
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place conditioning with morphine attenuated morphine-
induced CPP, whereas MTEP treatment during cocaine
conditioning did not affect the development of cocaine-
induced CPP. MTEP blocked the development of psycho-
motor sensitization to cocaine, but not morphine.
Place conditioning
MTEP attenuated morphine-induced CPP when 1 or 3 mg/
kg, but not when 10 mg/kg was co-administered during
conditioning. This suggests that mGlu5 receptors play a
role in mediating morphine reward. These results are in
agreement with other studies in which MPEP attenuated the
development of morphine-induced CPP (Popik and Wrobel
2002; Aoki et al. 2004; Herzig and Schmidt 2004).
However, other studies have shown that MPEP had no
effect on morphine CPP (McGeehan and Olive 2003) and
actually potentiated heroin-induced CPP (van der Kam
et al. 2009a). Because MTEP and MPEP can cause deficits
in spatial learning (Naie and Manahan-Vaughan 2004;
Gravius et al. 2008; Bikbaev et al. 2008), it is possible
that MTEP impaired learning, i.e., the establishment of an
association between the environmental cues in the
morphine-paired compartment and the rewarding properties
of the drug (see also Fendt and Schmid 2002; Rodrigues
et al. 2002; Gravius et al. 2005; Xu et al. 2009), without
effectively influencing the rewarding effects of morphine.
However, MTEP did not suppress cocaine-induced CPP,
which suggests that learning of an environment–reward
association was intact in MTEP-treated animals. It is
therefore unlikely that the effect of MTEP on morphine
CPP is the result of impairment in learning. We do not have
a straightforward explanation for the finding that 10 mg/kg
MTEP did not influence morphine CPP. It might be that an
off-target effect of MTEP is responsible for this lack of
effect. In vitro essays have shown that high concentrations
of MTEP inhibit monoamine oxidase A and NR1a/2B-
containing NMDA receptors, but it is unlikely that the dose
of 10 mg/kg, i.p., MTEP resulted in brain concentrations
high enough to elicit these effects (Cosford et al. 2003;
Nagel et al. 2007). Alternatively, the repeated injection of
10 mg/kg MTEP may have evoked tolerance to the effects
of the drug. Indeed, the repeated administration of MTEP
can lead to tolerance into its analgesic and anxiolytic effects
(Busse et al. 2004; Sevostianova and Danysz 2006).
In the present study, MTEP did not affect cocaine-induced
CPP. This suggests that stimulation of mGlu5 receptors is not
critical for cocaine reward. This finding stands in contrast to
studies showing that MPEP blocks the development of
cocaine CPP (Herzig and Schmidt 2004; McGeehan and
Olive 2003). Interestingly, recent studies have shown that
MPEP potentiates the development of CPP induced by
subeffective doses of cocaine, nicotine, ketamine, and heroin
(van der Kam et al. 2009a; Rutten et al. 2010). Since
effective doses of cocaine and morphine were used in the
present study, a potentiation of the development of CPP by
MTEP was not likely to be detected. However, the MPEP
that was used in these previous studies is a less selective
mGlu5 receptor antagonist than MTEP, since it can also bind
to NMDA receptors (O'Leary et al. 2000; Cosford et al.
2003). It is well known that NMDA receptor antagonists
block the development of cocaine and morphine CPP (Cervo
and Samanin 1995; Maldonado et al. 2007; Tzschentke and
Schmidt 1995; Tzschentke and Schmidt 1997) but can also
potentiate the reinforcing effects of drugs and have reinforc-
ing effects themselves (Vanderschuren et al. 1998). It is
therefore possible that the earlier observed effects with
MPEP on the development of CPP were the result of NMDA
Fig. 7 a Locomotor responses to morphine (1.0 mg/kg, s.c.) in
animals pretreated for 5 days with: saline plus saline (sal-sal; n=6),
saline plus 3.0 mg/kg morphine, s.c., (sal-morp; n=5), 1.0 mg/kg
MTEP, i.p., plus saline (mtep-sal; n=6) or 1.0 mg/kg MTEP, i.p., plus
3.0 mg/kg morphine, s.c. (mtep-morp; n=6), 3 weeks post-treatment.
b Locomotor responses to morphine (1.0 mg/kg, s.c.) in animals
pretreated for 5 days with: saline plus saline (sal-sal; n=5), saline plus
3.0 mg/kg morphine, s.c. (sal-morp; n=5), 0.5 mg/kg α-flupenthixol,
i.p., plus saline (flu-sal; n=5) or 0.5 mg/kg α-flupenthixol, i.p., plus
3.0 mg/kg morphine, s.c. (flu-morp; n=6), 3 weeks post-treatment.
Data are presented as mean ± S.E.M. distance traveled (in cm) per
10 min during habituation to the test cages (10–30 min), after a saline
injection (40–60 min), and after the morphine challenge (1.0 mg/kg, s.c.,
70–150 min)
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receptor blockade. Future studies must reveal whether MTEP
can augment the development of CPP induced by subeffec-
tive doses of drugs.
The results of the present study are consistent with the well-
established role of dopamine receptor stimulation in the
rewarding properties of cocaine and morphine (Koob et al.
1998; van Ree et al. 1999; Wise 2004; Pierce and Kumaresan
2006; but see Spyraki et al. 1982; Mackey and van der Kooy
1985). We used the non-selective dopamine receptor antago-
nist α-flupenthixol that targets both dopamine D1 and D2
receptors. The dopamine D1 receptor has widely been
implicated in drug reward. Multiple studies have shown that
the D1 receptor antagonist SCH23390 blocks the develop-
ment of both cocaine- and morphine-induced CPP (cocaine:
Cervo and Samanin 1995; Shippenberg and Heidbreder 1995;
Baker et al. 1998; Nazarian et al. 2004; morphine: Leone and
Di Chiara 1987; Shippenberg and Herz 1988; Acquas et al.
1989; Acquas and Di Chiara 1994; Manzanedo et al. 2001).
In contrast to dopamine D1 receptors, dopamine D2 receptors
do not seem to be critical for the development of cocaine-
induced CPP (Cervo and Samanin 1995; Shippenberg and
Heidbreder 1995; Nazarian et al. 2004). With regard to
morphine-induced CPP, there have been reports that dopamine
D2 receptor antagonists block the development of morphine-
induced CPP (Leone and Di Chiara 1987; Manzanedo et al.
2001), while others have reported no effect (Shippenberg and
Herz 1988).
In the Introduction we mentioned that mGlu5 receptors
may be involved in drug reward via downstream modulation
of mesolimbic dopamine activity. However, our results,
showing partially divergent effects of MTEP and α-
flupenthixol on drug-induced CPP, do not support this
possibility. Thus, whereas α-flupenthixol blocked the devel-
opment of both cocaine- and morphine–induced CPP, MTEP
attenuated only the development of morphine-induced CPP.
The rewarding properties of cocaine depend more strongly
on dopaminergic neurotransmission than morphine reward
(van Ree et al. 1999; Pierce and Kumaresan 2006).
Therefore, the finding that MTEP only attenuated the
process least dependent on dopaminergic neurotransmission
indicates that MTEP influences drug reward through
mechanisms that are relatively dopamine–independent. The
exact mechanism of action of MTEP on morphine-induced
CPP remains to be elucidated. Interestingly, stimulation of
nucleus accumbens mGlu5 receptors has been shown to
enhance endocannabinoid activity (Robbe et al. 2002), and
unlike cocaine reward the rewarding properties of opiates
strongly depend on endocannabinoid signaling (e.g., Cossu
et al. 2001; De Vries et al. 2003; for reviews see Maldonado
et al. 2006; Solinas et al. 2008). One intriguing possibility is
therefore that blockade of nucleus accumbens mGlu5
receptors reduces opioid-induced endocannabinoid activity,
which diminishes the rewarding properties of morphine.
Indeed, enhanced nucleus accumbens endocannabinoid activ-
ity plays a prominent role in heroin but not cocaine self-
administration, independent of nucleus accumbens dopamine
activity (Caille and Parsons 2003, 2006; Caille et al. 2007).
It can be excluded that MTEP or α-flupenthixol affected
place conditioning because of any aversive or rewarding
properties of the antagonists themselves. When MTEP or
α-flupenthixol was administered during place conditioning
in the absence of cocaine or morphine, neither substance
induced a preference or aversion for the antagonist-paired
compartment.
Taken together, the present study suggests that dopamine
receptors are critically involved in cocaine and morphine
reward and that mGlu5 receptors play an important role in
morphine but not cocaine reward.
Psychomotor sensitization
In the present study, α-flupenthixol was unable to alter the
development of cocaine- and morphine-induced locomotor
sensitization. This supports the notion that dopaminergic
neurotransmission is not critical for the induction of cocaine
and morphine sensitization (Vanderschuren and Kalivas
2000). Similar findings have been reported with both D1
and D2 receptor antagonists, i.e., SCH 23390, sulpride,
eticlopride, and YM-09151-2 (cocaine: Mattingly et al.
1994; Kuribara 1995; White et al. 1998; morphine: Vezina
and Stewart 1989; Jeziorski and White 1995). It is unlikely
that the dose of 0.5 mg/kg α-flupenthixol was too low to
affect the development of psychomotor sensitization. Even
though α-flupenthixol did not alter locomotor activity
during pretreatment sessions, this dose of α-flupenthixol
was sufficient to block the rewarding effects of cocaine in
the place conditioning experiment. Furthermore, it has been
repeatedly shown that doses of dopaminergic drugs that do
reduce the psychomotor stimulant effects of cocaine and
morphine do not block the development of sensitization
(Vezina and Stewart 1989; Mattingly et al. 1994; Jeziorski
and White 1995; Kuribara 1995; White et al. 1998).
MTEP blocked the development of cocaine-induced
psychomotor sensitization without affecting the acute
psychomotor responses to cocaine. Consistent with the
latter observation, Herzig and Schmidt (2004) have shown
that MPEP does not affect cocaine- and morphine-induced
psychomotor activity. However, they did not challenge their
animals with cocaine or morphine in the absence of MPEP
after a period of abstinence, which left the question on
whether mGlu5 receptors are involved in the development
of locomotor sensitization open. Previously, Ghasemzadeh
et al. (1999, 2009) have shown an increase in mGlu5
receptor mRNA level in the nucleus accumbens shell and
dorsolateral striatum and an augmented mGlu5 receptor
protein level in the synaptosomal membrane of the nucleus
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accumbens shell and core in cocaine-sensitized animals.
This suggests a link between the development of cocaine
sensitization and mGlu5 receptors, but ours is the first
pharmacological intervention study that demonstrates a
critical role for mGlu5 receptors in the development of
cocaine-induced psychomotor sensitization. In contrast,
even though repeated morphine treatment has been shown
to result in an increase in mGlu5 protein level in the
nucleus accumbens (Aoki et al. 2004), MTEP did not
attenuate morphine psychomotor sensitization.
The explanation for why mGlu5 receptors are involved
in the development of psychomotor sensitization to
cocaine but not to morphine might lie in the differential
interactions of these drugs with glutamatergic neurotrans-
mission. For instance, cocaine increases extracellular
glutamate levels in various brain regions of drug-naïve
animals (Smith et al. 1995; Reid et al. 1997; McKee and
Meshul 2005) and repeated cocaine administration results
in the sensitization of cocaine-induced extracellular gluta-
mate levels in the nucleus accumbens and ventral
tegmental area (Pierce et al. 1996; Reid and Berger
1996; Kalivas and Duffy 1998; Bell et al. 2000). In
contrast, morphine administration initially results in
decreases in extracellular glutamate levels in various brain
regions, including the nucleus accumbens and dorsal
striatum (Sepulveda et al. 1998; Desole et al. 1996; Enrico
et al. 1998). With repeated treatment, tolerance develops
to this effect of morphine on extracellular glutamate levels
(Sepulveda et al. 1998; Desole et al. 1996). Together, brain
glutamate release responds more strongly to cocaine than
to morphine, which makes it more likely that mGlu5
receptors become activated by repeated cocaine adminis-
tration than by morphine. In this regard, the dissociable
role of mGlu5 receptors in the development of cocaine and
morphine psychomotor sensitization is reminiscent of the
role of NMDA receptors in these processes. It is well
established that NMDA receptors are involved in the
development of cocaine-induced locomotor sensitization
(Scheggi et al. 2002; Vanderschuren and Kalivas 2000;
Wolf and Jeziorski 1993), but the evidence that NMDA
receptors are important for the development of morphine
sensitization is inconsistent (Jeziorski et al. 1994;
Tzschentke and Schmidt 1996; Vanderschuren et al.
1997; Ranaldi et al. 2000; Scheggi et al. 2002). Alterna-
tively, since morphine pretreatment lasted for 10 days,
compared to 5 days of cocaine pretreatment, the possibility
that tolerance to the effect of MTEP developed over
repeated dosing cannot be excluded. Thus, it might be that
tolerance to the effect of MTEP, although this has thus far
only been demonstrated for doses of 3 mg/kg and higher
(Busse et al. 2004; Sevostianova and Danysz 2006),
explains the lack of effect of MTEP on the development
of morphine sensitization.
Conclusions
The present study shows that the role of mGlu5 receptors in
reward and sensitization is distinct for morphine and
cocaine. Although mGlu5 receptor antagonists have been
proposed to hold promise for the treatment of drug
addiction, recent studies have shown that the role of the
mGlu5 receptor in addictive behavior is not as straightfor-
ward as initially assumed (van der Kam et al. 2009a;
2009b; Hao et al. 2010; Rutten et al. 2010). Therefore,
caution should be taken not to overgeneralize the anti-
addictive properties of mGlu5 receptor ligands.
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